Ochre Bio
Latest round
- Series A
Last raised
- Oct 2022
Total raised
- $40M
Investors
- 11
About Ochre Bio
Founded in 2019 and based in Oxford, UK, Ochre Bio Limited operates as a developer of AI-integrated drug development procedure for genomic medicines called deep phenotyping that helps in shutting down over-active genes for livers before transplant. The company was founded by the CEO Jack O'meara and Quin Wills. The company's product is focusing on developing a genomic medicine that uses an AI-integrated drug development procedure called deep phenotyping. The medicine focuses on shutting down the over-active genes that cause chronic liver diseases. The formula specifically targets the liver that will undergo transplants or under medication. The company's revenue is generated by the sales of its RNA medicines to its target market mostly patients that will undergo transplants and under medications. The company plans to expand its platform to identify and validate new liver targets.
Who invested in Ochre Bio
11 investors across 2 rounds
See all investors in Ochre Bio
Sign up free to see every VC on the cap table, the rounds they joined, and how much each round raised.
Questions about Ochre Bio
Who invested in Ochre Bio?
Ochre Bio has 11 investors on record across 2 venture rounds. Sign up free to see every VC on the cap table and the rounds they joined.
How much funding has Ochre Bio raised?
Ochre Bio has raised 2 venture rounds. Sign up free to see how much each round raised and the total.
When did Ochre Bio last raise money?
Ochre Bio's most recent round on record is a Series A, in Oct 2022.
What does Ochre Bio do?
Founded in 2019 and based in Oxford, UK, Ochre Bio Limited operates as a developer of AI-integrated drug development procedure for genomic medicines called deep phenotyping that helps in shutting down over-active genes for livers before transplant.
Where is Ochre Bio headquartered?
Ochre Bio is headquartered in Oxford, UK.
Which VCs invest in companies like Ochre Bio?
Among active investors with capital left to deploy, Index Ventures, Forbion, European Investment Bank and Highland Europe back biotechnology companies at Ochre Bio's stage. Their profiles are linked below.
VCs backing biotechnology startups at Series A
Raising like Ochre Bio? Find the right VCs.
Capital Atlas matches your startup to active investors by stage, sector and region.